228 related articles for article (PubMed ID: 26308942)
21. Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation.
Mercier C; Raynal C; Dahan L; Ortiz A; Evrard A; Dupuis C; Blesius A; Duluc M; Franceschini F; Giacometti S; Salas S; Milano G; Favre R; Seitz JF; Ciccolini J
Pharmacogenet Genomics; 2007 Oct; 17(10):841-4. PubMed ID: 17885621
[TBL] [Abstract][Full Text] [Related]
22. Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines.
Bjånes TK; Jordheim LP; Schjøtt J; Kamceva T; Cros-Perrial E; Langer A; Ruiz de Garibay G; Kotopoulis S; McCormack E; Riedel B
Drug Metab Dispos; 2020 Mar; 48(3):153-158. PubMed ID: 31871136
[TBL] [Abstract][Full Text] [Related]
23. An initial genetic analysis of gemcitabine-induced high-grade neutropenia in pancreatic cancer patients in CALGB 80303 (Alliance).
Innocenti F; Jiang C; Sibley AB; Denning S; Etheridge AS; Watson D; Niedzwiecki D; Hatch AJ; Hurwitz HI; Nixon AB; Furukawa Y; Kubo M; Crona DJ; Kindler HL; McLeod HL; Ratain MJ; Owzar K
Pharmacogenet Genomics; 2019 Aug; 29(6):123-131. PubMed ID: 30889042
[TBL] [Abstract][Full Text] [Related]
24. High incidence of severe neutropenia after gemcitabine-based chemotherapy in Chinese cancer patients with CDA 79A>C mutation.
Xu J; Zhou Y; Zhang J; Chen Y; Zhuang R; Liu T; Cai W
Clin Chim Acta; 2012 Aug; 413(15-16):1284-7. PubMed ID: 22546611
[TBL] [Abstract][Full Text] [Related]
25. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
Rajabpour A; Afgar A; Mahmoodzadeh H; Radfar JE; Rajaei F; Teimoori-Toolabi L
Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
[TBL] [Abstract][Full Text] [Related]
26. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.
Joerger M; Burgers JA; Baas P; Doodeman VD; Smits PH; Jansen RS; Vainchtein LD; Rosing H; Huitema AD; Beijnen JH; Schellens JH
Cancer Chemother Pharmacol; 2012 Jan; 69(1):25-33. PubMed ID: 21590444
[TBL] [Abstract][Full Text] [Related]
27. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma.
Wolff RA; Evans DB; Gravel DM; Lenzi R; Pisters PW; Lee JE; Janjan NA; Charnsangavej C; Abbruzzese JL
Clin Cancer Res; 2001 Aug; 7(8):2246-53. PubMed ID: 11489798
[TBL] [Abstract][Full Text] [Related]
28. A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors.
Brand R; Capadano M; Tempero M
Invest New Drugs; 1997; 15(4):331-41. PubMed ID: 9547676
[TBL] [Abstract][Full Text] [Related]
29. Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer.
Garcia-Cremades M; Melillo N; Troconiz IF; Magni P
Clin Transl Sci; 2020 May; 13(3):608-617. PubMed ID: 32043298
[TBL] [Abstract][Full Text] [Related]
30. CDA as a predictive marker for life-threatening toxicities in patients with AML treated with cytarabine.
Fanciullino R; Farnault L; Donnette M; Imbs DC; Roche C; Venton G; Berda-Haddad Y; Ivanov V; Ciccolini J; Ouafik L; Lacarelle B; Costello R
Blood Adv; 2018 Mar; 2(5):462-469. PubMed ID: 29490977
[TBL] [Abstract][Full Text] [Related]
31. Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis.
Kasuya K; Tsuchida A; Nagakawa Y; Suzuki Y; Suzuki M; Aoki T; Abe Y; Shimazu M; Itoi T; Sofuni A
Hepatogastroenterology; 2012; 59(117):1609-13. PubMed ID: 22155850
[TBL] [Abstract][Full Text] [Related]
32. Role of cytidine deaminase in toxicity and efficacy of nucleosidic analogs.
Serdjebi C; Milano G; Ciccolini J
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):665-72. PubMed ID: 25495470
[TBL] [Abstract][Full Text] [Related]
33. Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.
Tibaldi C; Camerini A; Tiseo M; Mazzoni F; Barbieri F; Vittimberga I; Brighenti M; Boni L; Baldini E; Gilli A; Honeywell R; Chartoire M; Peters GJ; Giovannetti E;
Br J Cancer; 2018 Nov; 119(11):1326-1331. PubMed ID: 30405211
[TBL] [Abstract][Full Text] [Related]
34. Lethal toxicity after administration of azacytidine: implication of the cytidine deaminase-deficiency syndrome.
Fanciullino R; Mercier C; Serdjebi C; Berda Y; Fina F; Ouafik L; Lacarelle B; Ciccolini J; Costello R
Pharmacogenet Genomics; 2015 Jun; 25(6):317-21. PubMed ID: 25850965
[TBL] [Abstract][Full Text] [Related]
35. Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples.
Giovannetti E; Laan AC; Vasile E; Tibaldi C; Nannizzi S; Ricciardi S; Falcone A; Danesi R; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2008 Jun; 27(6):720-5. PubMed ID: 18600531
[TBL] [Abstract][Full Text] [Related]
36. Associations of cytosine deaminase gene polymorphisms with effectiveness of gemcitabine/cisplatin chemotherapy in patients of Xinjiang Uyghur and Han nationality with non-small cell lung cancer.
Li J; Xu D; Huang J; Wang YN; Ma XP; Lin ZY; Gong P
Int J Biol Markers; 2019 Dec; 34(4):389-397. PubMed ID: 31603383
[TBL] [Abstract][Full Text] [Related]
37. Pharmacogenomics of gemcitabine metabolism: functional analysis of genetic variants in cytidine deaminase and deoxycytidine kinase.
Baker JA; Wickremsinhe ER; Li CH; Oluyedun OA; Dantzig AH; Hall SD; Qian YW; Ring BJ; Wrighton SA; Guo Y
Drug Metab Dispos; 2013 Mar; 41(3):541-5. PubMed ID: 23230131
[TBL] [Abstract][Full Text] [Related]
38. Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase.
Weizman N; Krelin Y; Shabtay-Orbach A; Amit M; Binenbaum Y; Wong RJ; Gil Z
Oncogene; 2014 Jul; 33(29):3812-9. PubMed ID: 23995783
[TBL] [Abstract][Full Text] [Related]
39. Postoperative adjuvant gemcitabine and concurrent radiation after curative resection of pancreatic head carcinoma: a phase II study.
Van Laethem JL; Demols A; Gay F; Closon MT; Collette M; Polus M; Houbiers G; Gastelblum P; Gelin M; Houtte PV; Closset J
Int J Radiat Oncol Biol Phys; 2003 Jul; 56(4):974-80. PubMed ID: 12829132
[TBL] [Abstract][Full Text] [Related]
40. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.
Bramhall SR; Schulz J; Nemunaitis J; Brown PD; Baillet M; Buckels JA
Br J Cancer; 2002 Jul; 87(2):161-7. PubMed ID: 12107836
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]